Loading match intelligence
Resolves Yes if the olpasiran phase 3 trial meets its primary endpoint, as reported by the sponsor in a press release or peer-reviewed publication by the close date.
Resolves Yes if Resolves Yes if the olpasiran phase 3 trial meets its primary endpoint, as reported by the sponsor in a press release or peer-reviewed publication by the close date.
Outcome verified from clinicaltrials.gov.
Trading on material non-public information is prohibited. Markets are for entertainment and informational purposes using free Pulse Credits — no real-money wagering. If you believe a participant has acted on inside information, please report it.
Analyzing this market…
